ArticleMolecular genetics & genomic medicine2019
Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer.
Article in Molecular genetics & genomic medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 30 citations in OpenAlex.
- Multi-omics data integration for enhanced cancer subtyping via interactive multi-kernel learning.Briefings in bioinformatics · 2025Article
- CENPF overexpression in bladder cancer cells enhances proliferation, migration, invasion, and apoptosis.Scientific reports · 2025Article
- Nano-delivery of miRNA inhibiting CENPF combined with cisplatin for bladder cancer treatment.RSC advances · 2025Article
- E2F1-driven CENPM expression promotes glycolytic reprogramming and tumorigenicity in glioblastoma.Cell biology and toxicology · 2024Article
- Integrated pan-cancer analysis of centromere protein F and experimental verification of its role and clinical significance in cholangiocarcinoma.Functional & integrative genomics · 2023Article
- Article
- CENPF promotes papillary thyroid cancer progression by mediating cell proliferation and apoptosis.Experimental and therapeutic medicine · 2021Article
- Construction and Validation of a Novel Eight-Gene Risk Signature to Predict the Progression and Prognosis of Bladder Cancer.Frontiers in oncology · 2021Article
- Low Expression of Keratin17 is Related to Poor Prognosis in Bladder Cancer.OncoTargets and therapy · 2021Article
- Emerging roles of N6-methyladenosine (mCell & bioscience · 2020Review
- Three-gene risk model in papillary renal cell carcinoma: a robust likelihood-based survival analysis.Aging · 2020Article
- Identification of key candidate genes associated with prognosis of lung adenocarcinoma by integrated bioinformatical analysis.Translational cancer research · 2020Article
- TOP2A and CENPF are synergistic master regulators activated in cervical cancer.BMC medical genomics · 2020Article
- Identification of early stage recurrence endometrial cancer biomarkers using bioinformatics tools.Oncology reports · 2020Observational
- Bioinformatics analysis to reveal key biomarkers for early and late hepatocellular carcinoma.Translational cancer research · 2020Article
- Screening and identification of genes associated with cell proliferation in cholangiocarcinoma.Aging · 2020Article
- Identification of Crucial Genes Associated With Immune Cell Infiltration in Hepatocellular Carcinoma by Weighted Gene Co-expression Network Analysis.Frontiers in genetics · 2020Article
- Identification and Validation of Novel Genes in Anaplastic Thyroid Carcinoma via Bioinformatics Analysis.Cancer management and research · 2020Article
- Weighted gene coexpression network analysis identifies a new biomarker of CENPF for prediction disease prognosis and progression in nonmuscle invasive bladder cancer.Molecular genetics & genomic medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe dreadful prognosis of nonmuscle invasive bladder cancer mainly results from the delay in recognition of individuals with a high risk of progression. Thus, the emphasis of this work lies in developing valuable biomarkers that is conducive to accurately predicting the progression of NMIBC.
methodsMicroarray data from GSE32894 including 209 NMIBC samples were performed by weighted gene coexpression network analysis (WGCNA), which could find modules of highly correlated genes and relate modules to external sample traits. Besides, we constructed a protein-protein interaction to facilitate screening the hub gene. At last, we used RNA-seq and microarray data and clinical information from ArrayExpress (E-MTAB-4321) and GSE13507 to select and validate the candidate gene.
resultsIn current paper, blue module of 13 gene coexpression clusters we identified was selected as the key modules. Seven genes namely: CDCA8, CENPF, MCM6, MELK, PRC1, STIL, and TPX2 have been identified as candidate genes. Notably, among them, only elevated CENPF in NIMBC tissue was closely associated with low progression-free survival (PFS) and overall survival (OS) rate in three datasets and had a large area under receiver operating characteristic (ROC) curve. Finally, CENPF was identified as an effective biomarker in NMIBC.
conclusionTherefore, our findings submit a new progressive and prognostic molecular marker and therapeutic target for NMIBC. Moreover, these genes that deserve to be further researched may improve the comprehension about the occurrence and development of superficial bladder cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.